Across the past 12 months, Lexaria Bioscience insiders reported no open-market purchases or sales.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Christopher Bunka | Director | 43,139 | 0 | 43,139 | 85.8% | 18 Mar, 2026 |
| 2 | Richard Christopher | Chief Executive Officer | 4,333 | 0 | 4,333 | 8.6% | 30 Jul, 2025 |
| 3 | William Edward Mckechnie | Director | 1,213 | 0 | 1,213 | 2.4% | 30 Jul, 2025 |
| 4 | Albert L Jr Reese | Director | 728 | 0 | 728 | 1.4% | 25 May, 2022 |
| 5 | John Martin Docherty | President Cso | 358 | 0 | 358 | 0.7% | 30 Jul, 2025 |
| 6 | Catherine C. Turkel | Director | 307 | 0 | 307 | 0.6% | 13 Aug, 2024 |
| 7 | Gregory Downey | Chief Financial Officer | 130 | 0 | 130 | 0.3% | 18 Oct, 2022 |
| 8 | Vanessa Carle | Secretary | 50 | 0 | 50 | 0.1% | 30 Jul, 2025 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 17 Mar, 2026 | Christopher Bunka | Director | Disposed G | 100,000 | $0.00 | $0 | 18,236 | Direct |
| 29 Jul, 2025 | Vanessa Carle | Secretary | Acquired P | 750 | $13.65 | $10.24K | 50 | Direct |
| 29 Jul, 2025 | Richard Christopher | Chief Executive Officer | Acquired P | 15,000 | $13.64 | $204.62K | 4,333 | Direct |
| 29 Jul, 2025 | John Martin Docherty | President Cso | Acquired P | 5,376 | $13.92 | $74.83K | 358 | Direct |
| 29 Jul, 2025 | William Edward Mckechnie | Director | Acquired P | 5,000 | $13.59 | $67.97K | 1,213 | Direct |
| 29 Jul, 2025 | Christopher Bunka | Director | Acquired P | 15,600 | $13.82 | $215.63K | 18,001 | Indirect |
| 30 Jul, 2025 | Christopher Bunka | Director | Acquired P | 11,900 | $13.70 | $162.99K | 18,794 | Indirect |
| 15 May, 2025 | Michael Elliot Shankman | Chief Financial Officer | Acquired A | 50,000 | $0.00 | $0 | 6,667 | Direct |
| 15 May, 2025 | Baljinder Bhullar | Director | Acquired A | 11,000 | $0.00 | $0 | 733 | Direct |
| 15 May, 2025 | Richard Christopher | Chief Executive Officer | Acquired A | 150,000 | $0.00 | $0 | 23,333 | Direct |
| 15 May, 2025 | Vanessa Carle | Secretary | Acquired A | 15,000 | $0.00 | $0 | 5,000 | Direct |
| 15 May, 2025 | John Martin Docherty | President | Acquired A | 150,000 | $0.00 | $0 | 20,722 | Direct |
| 15 May, 2025 | Albert L Jr Reese | Director | Acquired A | 11,000 | $0.00 | $0 | 2,867 | Direct |
| 15 May, 2025 | Christopher Bunka | Director | Acquired A | 11,000 | $0.00 | $0 | 12,322 | Direct |
| 15 May, 2025 | Nicholas W Baxter | Director | Acquired A | 11,000 | $0.00 | $0 | 4,200 | Direct |
| 15 May, 2025 | William Edward Mckechnie | Director | Acquired A | 11,000 | $0.00 | $0 | 4,200 | Direct |
| 07 Jan, 2025 | Christopher Bunka | Director | Acquired A | 100,000 | $0.00 | $0 | 24,903 | Direct |
| 02 Dec, 2024 | Richard Christopher | Chief Executive Officer | Acquired P | 22,828 | $33.65 | $768.25K | 1,522 | Direct |
| 03 Dec, 2024 | Richard Christopher | Chief Executive Officer | Acquired P | 27,172 | $37.08 | $1.01Mn | 3,333 | Direct |
| 12 Aug, 2024 | Catherine C. Turkel | Director | Acquired P | 1,600 | $46.95 | $75.12K | 207 | Direct |